Positive News SentimentPositive NewsNASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis $17.31 +0.03 (+0.17%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$17.32 +0.02 (+0.09%) As of 08/29/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eton Pharmaceuticals Stock (NASDAQ:ETON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eton Pharmaceuticals alerts:Sign Up Key Stats Today's Range$17.06▼$17.5050-Day Range$13.50▼$17.4652-Week Range$4.47▼$21.48Volume160,324 shsAverage Volume333,677 shsMarket Capitalization$464.25 millionP/E RatioN/ADividend YieldN/APrice Target$29.67Consensus RatingBuy Company Overview Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Read More Eton Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreETON MarketRank™: Eton Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 565th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEton Pharmaceuticals has received no research coverage in the past 90 days.Read more about Eton Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow in the coming year, from ($0.14) to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is -108.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is -108.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 19.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eton Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.48% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Eton Pharmaceuticals has recently increased by 8.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.48% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Eton Pharmaceuticals has recently increased by 8.85%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment1.86 News SentimentEton Pharmaceuticals has a news sentiment score of 1.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eton Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest9 people have searched for ETON on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows2 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,178,031.00 in company stock.Percentage Held by Insiders16.03% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETON Stock News HeadlinesInsider Selling: Eton Pharmaceuticals (NASDAQ:ETON) CFO Sells 2,631 Shares of StockAugust 21, 2025 | insidertrades.comEton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare ConferenceAugust 20, 2025 | globenewswire.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.August 30 at 2:00 AM | Brownstone Research (Ad)Craig-Hallum Sticks to Its Buy Rating for Eton Pharmaceuticals (ETON)August 17, 2025 | theglobeandmail.comEton Pharmaceuticals Reports Strong Q2 Growth Amid ChallengesAugust 13, 2025 | msn.comEton targets $80M revenue run-rate in Q3 2025 as product launches accelerateAugust 8, 2025 | msn.comEton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comEton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With OptionsAugust 8, 2025 | seekingalpha.comSee More Headlines ETON Stock Analysis - Frequently Asked Questions How have ETON shares performed this year? Eton Pharmaceuticals' stock was trading at $13.32 at the beginning of 2025. Since then, ETON stock has increased by 30.0% and is now trading at $17.31. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.09. The firm earned $18.93 million during the quarter, compared to the consensus estimate of $16.71 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 0.73% and a negative net margin of 7.10%. Read the conference call transcript. When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation served as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' top institutional shareholders include Opaleye Management Inc. (10.66%), EcoR1 Capital LLC (7.57%), Geode Capital Management LLC (2.21%) and Divisadero Street Capital Management LP (1.86%). Insiders that own company stock include Opaleye Management Inc, Sean Brynjelsen, David Krempa and James R Gruber. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/07/2025Today8/30/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETON CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Eton Pharmaceuticals$29.67 High Price Target$35.00 Low Price Target$26.00 Potential Upside/Downside+71.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.82 million Net Margins-7.10% Pretax Margin-6.92% Return on Equity-0.73% Return on Assets-0.22% Debt Debt-to-Equity Ratio1.14 Current Ratio1.77 Quick Ratio1.16 Sales & Book Value Annual Sales$39.01 million Price / Sales11.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book19.45Miscellaneous Outstanding Shares26,820,000Free Float22,519,000Market Cap$464.25 million OptionableOptionable Beta1.13 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ETON) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.